InvestorPlace
7 Dividend Aristocrats That Will Outlive Us All
Most long-term investors love passive income stocks. Therefore, today we introduce seven “Dividend Aristocrats,” or businesses that have increased the base dividend every year for the past 25 years. According to metrics from S&P Global (NYSE:SPGI), “Since 1926, dividends have contributed to approximately one-third of total return while capital appreciations have contributed two-thirds. Therefore, both sustainable dividend income and capital appreciation potential are important to total return expectations.” Over the past year, the S&P 500 Dividend Aristocrats Index has returned over 6%. By comparison, the Dow Jones Industrial Average (DJIA) has increased by 5%.InvestorPlace – Stock Market News, Stock Advice & Trading Tips Solid businesses with wide moats tend to be able to generate stable revenues and strong cash flows in most years, even in volatile times or recessions. In fact, many such firms end up gaining market share at the expense of weaker businesses that might simply fight to stay alive during economically tough times. Meanwhile, companies that consistently grow dividends are in effect saying that they are committed to sharing the success of the business with stockholders. With that information, here are seven Dividend Aristocrats that deserve your attention in 2021: 7 Airline Stocks Being Fueled by Vaccine News AbbVie (NYSE:ABBV) Albemarle (NYSE:ALB) Automatic Data Processing (NASDAQ:ADP) Chubb (NYSE:CB) Emerson Electric (NYSE:EMR) ProShares S&P 500 Dividend Aristocrats ETF (BACS:NOBL) Sysco (NYSE:SYY) Dividend Aristocrats: AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com 52-week range: $62.55 – $113.41 1-year price change: Up 23.82% Dividend yield: 4.71% Illinois-based biopharma group AbbVie is our first Dividend Aristocrat. It has numerous research and development (R&D) centers and manufacturing facilities globally. Several of its therapeutic areas include eye care, gastroenterology, immunology, neuroscience, oncology, rheumatology, virology, and women’s health. In addition, its Allergan Aesthetics portfolio includes products, such as Botox Cosmetics, fillers, and implants. The last quarterly report showed non-GAAP adjusted net revenues of $12.882 billion, an increase of 4.1% year-over-year (YoY). Net earnings of $2.31 billion meant an increase of 22.5% YoY. Adjusted diluted EPS was $2.83, up 21% YoY. Cash and equivalents stood at $7.89 billion. CEO Richard A. Gonzalez cited, “Results from key growth products – including Skyrizi, Rinvoq and Ubrelvy – continue to track ahead of our expectations, our aesthetics portfolio is demonstrating a strong V-shaped recovery, our hematologic-oncology franchise is delivering double-digit growth and we’re advancing numerous attractive late-stage pipeline programs.” The company has in-demand therapies and products…
Read More: Social Media Analytics Market Research Report – Global Forecast to 2024 –